Detalhe da pesquisa
1.
Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells.
Cell
; 167(2): 566-580.e19, 2016 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27716510
2.
Trial of Lixisenatide in Early Parkinson's Disease.
N Engl J Med
; 390(13): 1176-1185, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598572
3.
Survival of a Novel Subset of Midbrain Dopaminergic Neurons Projecting to the Lateral Septum Is Dependent on NeuroD Proteins.
J Neurosci
; 37(9): 2305-2316, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28130357
4.
Evidence for a Notch1-mediated transition during olfactory ensheathing cell development.
J Anat
; 229(3): 369-83, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27271278
5.
Foxa1 and foxa2 are required for the maintenance of dopaminergic properties in ventral midbrain neurons at late embryonic stages.
J Neurosci
; 33(18): 8022-34, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23637192
6.
Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.
Eur J Neurosci
; 39(6): 1042-1056, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24372914
7.
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.
J Parkinsons Dis
; 14(4): 657-666, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38578902
8.
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.
J Parkinsons Dis
; 13(4): 427-439, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37302040
9.
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.
J Parkinsons Dis
; 12(4): 1073-1082, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35527571
10.
Waiting for PARIS-A Biological Target in Search of a Drug.
J Parkinsons Dis
; 12(1): 95-103, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34744054
11.
Polyclonal T-cell reconstitution of X-SCID recipients after in utero transplantation of lymphoid-primed multipotent progenitors.
Blood
; 113(19): 4790-8, 2009 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-19074736
12.
Drug Repurposing for Parkinson's Disease: The International Linked Clinical Trials experience.
Front Neurosci
; 15: 653377, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33815053
13.
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.
J Parkinsons Dis
; 11(3): 891-903, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34151864
14.
The wrong James Parkinson.
Pract Neurol
; 15(2): 148, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25561574
15.
Novel approaches to counter protein aggregation pathology in Parkinson's disease.
Prog Brain Res
; 252: 451-492, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32247372
16.
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
J Parkinsons Dis
; 10(3): 757-774, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32741777
17.
Hyperosmotic stress induces cell-dependent aggregation of α-synuclein.
Sci Rep
; 9(1): 2288, 2019 02 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30783136
18.
Erythromyeloid-Derived TREM2: A Major Determinant of Alzheimer's Disease Pathology in Down Syndrome.
J Alzheimers Dis
; 61(3): 1143-1162, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29278889
19.
CD24 expression does not affect dopamine neuronal survival in a mouse model of Parkinson's disease.
PLoS One
; 12(2): e0171748, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28182766
20.
Neuroprotective Effect of TREM-2 in Aging and Alzheimer's Disease Model.
J Alzheimers Dis
; 55(1): 199-217, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27662313